Why Is Bio-Path (BPTH) Stock Up 20% Today?

Prexigebersen is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax. The big news is the company presented interim data from this study. Bio-Path CEO Peter Nielsen said the following about this news in a press release: BPTH Stock Movement Today Investors will want to keep reading for more of the most recent stock market news today! On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions, InvestorPlace does not publish comme ...